Overcoming undesirable hERG potency of chemokine receptor antagonists using baseline lipophilicity relationships

Journal of Medicinal Chemistry

Volumn 51, Issue 5, 2008, Pages 1162-1178

  Shamovsky, Igor ^a   Connolly, Stephen ^b   David, Laurent ^a   Ivanova, Svetlana ^a   Nordén, Bo ^a   Springthorpe, Brian ^b   Urbahns, Klaus ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; POTASSIUM CHANNEL HERG;

ARTICLE; LIPOPHILICITY; PHARMACOPHORE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BINDING SITES; CHEMISTRY, PHYSICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; POTASSIUM CHANNEL BLOCKERS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, CHEMOKINE;

EID: 41649092655     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070543k     Document Type: Article

References (110)

1. Testai, L.; Bianucci, A. M.; Massarelli, I.; Breschi, M. C.; Martinotti, E.; Calderone, V. Torsadogenic cardiotoxicity of antipsychotic drags: A structural feature, potentially involved in the interaction with cardiac hERG potassium channels. Curr. Med. Chem. 2004, 11, 2691-2706.
2. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440, 463-469.
3. Stansfeld, P. J.; Sutcliffe, M. J.; Mitcheson, J. S. Molecular mechanisms for drag interactions with hERG that cause long QT syndrome. Expert Opin. Drug Metab. Toxicol. 2006, 2, 81-94.
4. + channel blockade: Current knowledge and strategies for the early prediction during drug development. Med. Res. Rev. 2005, 25, 133-166.
5. Price, D. A.; Armour, D.; de Groot, M.; Leishman, D.; Napier, C.; Perros, M.; Stammen, B. L.; Wood, A. Overcoming hERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg. Med. Chem. Lett. 2006, 16, 4633-4637.
6. De Ponti, F.; Poluzzi, E.; Montanaro, N. Organizing evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs; A call for consensus. Eur. J. Clin. Pharmacol. 2001, 57, 185-209.
7. Aronov, A. M. Predictive in silico modelling for hERG channel blockers. Drug Discovery Today 2005, 10, 149-155.
8. Armer, R. E.; Morris, I. D. Trends in early drug safety. Drug News Perspect. 2004, 17, 143-148.
9. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J. Med. Chem. 2006, 49, 5029-5046.
10. (a) Anonymous. ICH S7B: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals; European Medicines Agency: London, 2005; 25 May, CPMP/ICH/423/02.
11. (b) Anonymous. ICH E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; European Medicines Agency: London, 2005; 25 May, CPMP/ICH/2/04.
12. Mitcheson, J. S.; Chen, J.; Lin, M.; Culberson, C.; Sanguinetti, M. C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 12329-12333.
13. Ekins, S.; Crumb, W. J.; Sarazan, R. D.; Wikel, J. H.; Wrighton, S. A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 2002, 301, 427-434.
14. + channel. A model for bad behavior. J. Med. Chem. 2003, 46, 2017-2022.
15. Zolotoy, A. B.; Plouvier, B. P.; Beatch, G. B.; Hayes, E. S.; Wall, R. A.; Walker, M. J. A. Physicochemical determinants for drag induced blockade of hERG potassium channels: Effects of charge and charge shielding. Curr. Med. Chem. 2003, 1, 225-241.
16. Bains, W.; Basman, A.; White, C. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog. Biophys. Mol. Biol. 2004, 86, 205-233.
17. (a) Song, M.; Clark, M. Development and evaluation of an in silico model for hERG binding. J. Chem. Inf. Model. 2006, 4, 392-400.
18. (b) Clark, M.; Song, M. Fragment based prediction of hERG binding. The 38th ACS Middle Atlantic Regional Meeting, Hershey, PA, June, 2006; MRM-520.
19. Cianchetta, G.; Li, Y.; Kang, J.; Rampe, D.; Fravolini, A.; Cruciani, G.; Vaz, R. J. Predictive models for hERG potassium channel blockers. Bioorg. Med. Chem. Lett. 2005, 15, 3637-3642.
20. Seierstad, M.; Agrafions, D. K. A QSAR model of hERG binding using a large, diverse, and internally consistent training set. Chem. Biol. Drug Des. 2006, 67, 284-296.
21. Perry, M.; Stansfeld, P. J.; Leaney, J.; Wood, C.; de Groot, M. J.; Leishman, D.; Sutcliffe, M. J.; Mitcheson, J. S. Drug binding interactions in the inner cavity of hERG channels: Molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol. Pharmacol. 2006, 69, 509-519.
22. Morgan, T. K., Jr.; Sullivan, M. E. An overview of Class III electrophysiological agents: A new generation of antiarrhythmic therapy. Prog. Med. Chem. 1992, 29, 65-108.
23. + channel blockers. J. Med. Chem. 2002, 45, 3844-3853.
24. + channel blockers. Bioorg. Med. Chem. 2004, 12, 2307-2315.
25. Aronov, A. M. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. J. Med. Chem. 2006, 49, 6917-6921.
26. + channel using docking and molecular dynamics methods. FEBS Lett. 2005, 579, 2939-2944.
27. Waring, M. J.; Johnstone, C. A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett. 2007, 17, 1759-1764.
28. Pearlstein, R. A.; Vaz, R. J.; Kang, J.; Chen, X.-L.; Preobrazhenskaya, M.; Shchekotikhin, A. E.; Korolev, A. M.; Lysenkova, L. N.; Miroshnikova, O. V.; Hendrix, J.; Rampe, D. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modelling approaches. Bioorg. Med. Chem. Lett. 2003, 13, 1829-1835.
29. + channel. J. Pharmacol. Exp. Ther. 2001, 299, 1007-1012.
30. 2A receptor antagonists. J. Med. Chem. 2001, 44, 1603-1614.
31. 1 receptor antagonists. II. Bioorg. Med. Chem. Lett. 2002, 12, 1759-1762.
32. kr currents in a case report of drug-induced cardiac arrhythmia. Br. J. Pharmacol. 2002, 137, 892-900.
33. 2A receptor antagonists. J. Med. Chem. 2002, 45, 492-503.
34. Fraley, M. E.; Arrington, K. L.; Buser, C. A.; Cieko, P. A.; Coll, K. E.; Fernandez, C.; Hartman, G. D.; Hoffman, W. F.; Lynch, J. J.; McFall, R. C.; Ricken, K.; Singh, S.; Thomas, K. A.; Wong, B. K. Optimization of the indolyl quinoline class of KDR (VEGFR-2) kinase inhibitors: Effects of 5-amido- and 5-sulfonamido-indolyl groups on pharmacokinetics of hERG binding. Bioorg. Med. Chem. Lett. 2004, 14, 351-355.
35. 2A ligands for the treatment of insomnia. Bioorg. Med. Chem. Lett. 2005, 15, 3665-3669.
36. Zhu, B.-Y.; Jia, Z. J.; Zhang, P.; Su, T.; Huang, W.; Goldman, E.; Tumas, D.; Kadambi, V.; Eddy, P.; Sinha, U.; Scarborough, R. M.; Song, Y. Inhibitory effect of carboxylic acid group on hERG binding. Bioorg. Med. Chem. Lett. 2006, 16, 5507-5512.
37. Springthorpe, B. hERG: One channel you don't want to tune in to!! The 2nd Anglo-Swedish Medicinal Chemistry Symposium, Åre, Sweden March, 2005.
38. (b) Springthorpe, B. The hERG channel: Tuned in? Chemical strategies for dialing out an off-target source of candidate failure. The 232nd ACS National Meeting; San Francisco, CA, September, 2006.
39. Bell, I. M.; Gallicchio, S. N.; Abrams, M.; Beshore, D. C.; Buser, C. A.; Culberson, J. C.; Davide, J.; Ellis-Hutchings, N.; Fernandez, C.; Gibbs, J. B.; Graham, S. L.; Hartman, G. D.; Heimbrook, D. C.; Honmick, C. F.; Huff, J. R.; Kassahun, K.; Koblan, K. S.; Kohl, N. E.; Lobell, R. B.; Lynch, J. J.; Miller, P. A.; Omer, C. A.; Rodrigues, A. D.; Walsh, E. S.; Williams, T. M. Design and biological activity of (S)-4-(5-{[1-(3-chlorobenzyl)-2-oxopyrrolidin-3- ylamino]methyl}-imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltrasferase inhibitor with excellent cell potency. J. Med. Chem. 2001, 44, 2933-2949.
40. Friesen, R. W.; Ducharme, Y.; Ball, R. G.; Blouin, M.; Boulet, L.; Côté, B.; Frenette, R.; Girard, M.; Guay, D.; Huang, Z.; Jones, T. R.; Laliberté, F.; Lynch, J. J.; Mancini, J.; Martins, E.; Masson, P.; Muise, E.; Pon, D. J.; Siegl, P. K. S.; Styhler, A.; Tsou, N. N.; Turner, M. J.; Young, R. N.; Girard, Y. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: Structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity. J. Med. Chem. 2003, 46, 2413-2426.
41. Vaz, R. J.; Gao, Z.; Pribish, J.; Chen, X.; Levell, J.; Davis, L.; Albert, E.; Brollo, M.; Ugolini, A.; Cramer, D. M.; Cairns, J.; Sides, K.; Liu, F.; Kwong, J.; Kang, J.; Rebello, S.; Elliot, M.; Lim, H.; Chellaraj, V.; Singleton, R. W.; Li, Y. Design of bivalent ligands using hydrogen bond linkers: Synthesis and evaluation of inhibitors of human β-tryptase. Bioorg. Med. Chem. Lett. 2004, 14, 6053-6056.
42. kr potassium channel blockers: Novel class III antiarrhythmic agents. Bioorg. Med. Chem. Lett. 2004, 14, 4771-4777.
43. Kubinyi, H. Lipophilicity and drag activity. Prog. Drug. Res. 1979, 23, 97-198.
44. Davis, A. M.; Dixon, J.; Logan, C. J.; Payling, D. W. Accelerating the progress of drag discovery. In Pharmacokinetic challenges in drug discovery; Pelkonen, O., Baumann, A., Reichel, A., Eds.; Springer: NY, 2002; pp 1-32,E. Schering Research Foundation, Workshop 37.
45. 2 based on a 1,3-disubstituted propan-2-one skeleton. J. Med. Chem. 2002, 45, 1348-1362.
46. Davis, A. M.; Teague, S. J. Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis. Angew. Chem., Int. Ed. 1999, 38, 736-749.
47. DeLano, W. L.; Ultsch, M. H.; de Vos, A. M.; Wells, J. A. Convergent solutions to binding at a protein-protein interface. Science 2000, 287, 1279-1283.
48. Lewis, D. F. V.; Dickins, M. Baseline lipophilicity relationships in human cytochromes P450 associated with drag metabolism. Drug Metab. Rev. 2003, 35, 1-18.
49. Lewis, D. F. V. Quantitative structure-activity relationships (QSARs) for substrates of human cytochromes P450 CYP2 family enzymes. Toxicol. In Vitro 2004, 18, 89-97.
50. Lewis, D. F. V.; Jacobs, M. N.; Dickins, M. Compound lipophilicity for substructure binding to human P450s in drug metabolism. Drug Discovery Today 2004, 9, 530-537.
51. Overton, E. Studien über die Narkose, Zugleich ein Beitrag zur allgemeinen Pharmakologie; Gustav Fischer: Jena, 1901; pp 1-195.
52. Meyer, H. H. Theorie der Alkoholnarkose. Arch. Exp. Pathol. Pharmakol. 1899, 42, 109-118.
53. Gao, Z.; Metz, W. A. Unraveling the chemistry of chemokine receptor ligands. Chem. Rev. 2003, 103, 3733-3752.
54. Dragic, T.; Trkola, A.; Thompson, D. A. D.; Cormier, E. G.; Kajumo, F. A.; Maxwell, E.; Lin, S. W.; Ying, W.; Smith, S. O.; Sakmar, T. P.; Moore, J. P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5639-5644.
55. Westby, M.; van der Ryst, E. CCR5 antagonists: Host-targeted antivirals for the treatment of HIV infection. Antiviral Chem. Chemother. 2005, 16, 339-354.
56. Horak, R. BX471: A CCR1 antagonist with anti-inflammatory activity in man. Mini-Rev. Med. Chem. 2005, 5, 791-804.
57. De Lucca, G. V. Recent developments in CCR3 antagonists. Curr. Opin. Drug Discovery Dev. 2006, 9, 516-524.
58. Lien, E. J. C.; Hansch, C.; Anderson, S. M. Structure-activity correlations for antibacterial agents on gram-positive and gram-negative cells. J. Med. Chem. 1968, 11, 430-441.
59. Seeman, P.; Roth, S.; Schneider, H. The membrane concentrations of alcohol anesthetics. Biochim. Biophys. Acta 1971, 225, 171-184.
60. Kubinyi, H. 2D QSAR models: Hansch and Free-Wilson analyses. In Computational Medicinal Chemistry for Drug Discovery; Bultinck, P., De Winter, H., Langenaeker, W., Tollenaere, J. P., Eds.; Marcel Dekker: New York, Basel, 2004; pp 539-570.
61. Rekker, R. F. The history of drug research: From Overton to Hansch. Quant. Struct.-Act. Relat. 1992, 11, 195-199.
62. Ferguson, J. The use of chemical potentials as indices of toxicity. Proc. R. Soc. London, Ser. B 1939, B127, 387-404.
63. Hansch, C.; Zhang, L. Quantitative structure-activity relationships of cytochrome P-450. Drug Metab. Rev. 1993, 25, 1-48.
64. Butora, G.; Morrielloo, G. J.; Kothandaraman, S.; Guiadeen, D.; Pasternak, A.; Parsons, W. H.; MacCoss, M.; Vicario, P. P.; Cascieri, M. A.; Yang, L. 4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties. Bioorg. Med. Chem. Lett. 2006, 16, 4715-4722.
65. Bertagna, A. M.; Barrick, D. Nonspecific hydrophobic interactions stabilize an equilibrium intermediate of apomyoglobin at a key position within the AGH region. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 12514-12519.
66. VanDer Kamp, K. A.; Qiang, D.; Aburub, A.; Wurster, D. E. Modified Langmuir-like model for modeling the adsorption from aqueous solutions by activated carbons. Langmuir 2005, 21, 217-224.
67. Ruben, A. J.; Kiso, Y.; Freire, E. Overcoming roadblocks in lead optimization: a thermodynamic perspective. Chem. Biol. Drug Des. 2006, 67, 2-4.
68. Free, S. M., Jr.; Wilson, J. W. A mathematical contribution to structure-activity studies. J. Med. Chem. 1964, 7, 395-399.
69. Stansfeld, P. J.; Gedeck, P.; Gosling, M.; Cox, B.; Mitcheson, J. S.; Sutcliffe, M. J. Drug block of the hERG potassium channel: insight from modeling. Proteins: Struct., Funct., Bioinformatics 2007, 68, 568-580.
70. Qiu, D.; Shenkin, P. S.; Hollinger, F. P.; Still, W. C. The GB/SA continuum model for solvation. A fast analytical method for the calculation of approximate Born radii. J. Phys. Chem. A 1997, 101, 3005-3014.
71. + selectivity filter: Charge balance and coupling of ion binding to a protein conformational change underlie high conduction rates. J. Mol. Biol. 2003, 333, 965-975.
72. + channels. Mol. Pharmacol. 2001, 60, 1343-1348.
73. + channels by vesnarinone. Mol. Pharmacol. 2001, 60, 244-253.
74. Mitcheson, J. S.; Chen, J.; Sanguinetti, M. C. Trapping of a methanesulfonanilide by closure of the hERG potassium channel activation gate. J. Gen. Physiol. 2000, 115, 229-239.
75. Mitcheson, J. S.; Perry, M. D. Molecular determinants of high-affinity drug binding to hERG channels. Curr. Opin. Drug Discovery Dev. 2003, 6, 667-674.
76. + channel. Nature 2003, 423, 33-41.
77. +-sensitive family of ion channels using a comprehensive alignment and the KcsA channel structure. Biophys. J. 2003, 84, 2929-2942.
78. Jiang, Y.; Lee, A.; Chen, J.; Cadene, M.; Chait, B. T.; MacKinnon, R. The open pore conformation of potassium channels. Nature 2002, 417, 523-526.
79. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
80. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide; A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 2004, 47, 1750-1759.
81. (a) Bodkin, M.; Eriksson, T.; Hansen, P.; Hemmerling, M.; Henriksson, K.; Klingstedt, T.; Pettersson, L. Preparation of substituted 1-phenoxy-3- pyrrolidino(or piperidino)propan-2-ols as chemokine receptor modulators. PCT Int. Appl. WO2001062728, 2001, 191.
82. (b) Eriksson, T.; Klingstedt, T.; Mussie, T. Preparation of substituted 1-benzyl-4-piperidinamines as chemokine receptor modulators. PCT Int. Appl WO2001098273, 2001, 64.
83. (a) Hossain, N.; Ivanova, S.; Mensonides-Harsema, M. Preparation of tricyclic spiropiperidines or spiropyrrolidines useful against disorders affected by modulation of chemokine receptors. PCT Int. Appl. WO2004005295, 2004, 281.
84. (b) Hossain, N.; Ivanova, S. Preparation of tricyclic spiropiperidines as modulators of chemokine receptor activity. PCT Int. Appl. WO2005061499, 2005, 70.
85. (c) Hossain, N.; Ivanova, S.; Mensonides-Harsema, M. Preparation of spiroheterocyclic-piperidine or -pyrrolidine derivatives as chemokine receptor modulators. PCT Int. Appl. WO2005054249, 2005, 54.
86. (d) Baxter, A.; Hossain, N.; Ivanova, S.; Mensonides-Harsema, M.; Pimm, A.; Reuberson, J. Preparation of N-(3-phenoxy-2-hydroxypropyl)-tricyclic spiropiperidine derivatives as modulators of chemokine receptor activity. PCT Int. Appl. WO2005049620, 2005, 74.
87. (a) Luckhurst, C.; Perry, M.; Springthorpe, B. Preparation of piperidine derivatives for use in the treatment of chemokine mediated disease states. PCT Int. Appl. WO2004029041, 2004, 72.
88. (b) Luckhurst, C.; Perry, M.; Springthoipe, B. Preparation of piperidine derivatives for the treatment of chemokine or H1 mediated disease state. PCT Int. Appl. WO2004085423, 2004, 44.
89. (c) Caffrey, M.; Luckhurst, C.; Mochel, T.; Perry, M.; Springthorpe, B. A preparation of (piperidinylmethyl)-piperidine derivatives, useful for the treatment of chemokine mediated diseases. PCT Int. Appl. WO2004087659, 2005, 67.
90. (d) Luckhurst, C.; Mochel, T.; Perry, M.; Springthorpe, B.; Stein, L. Preparation of 1-aryl (aryloxy)- or (arylmethyl)-piperidinemethylpiperidines as histamine Hl receptor binding agents for treatment of chemokine-mediated diseases. PCT Int. Appl. WO2004099144, 2004, 72.
91. (e) Mochel, T.; Perry, M.; Springthorpe, B. Preparation of piperidine derivatives for the treatment of chemokine mediated diseases. PCT Int. Appl. WO2005097775, 2005, 57.
92. (a) Bladh, H.; Connolly, S.; Dyke, H. J.; Lisius, A.; Price, S.; Shamovsky, I.; Van den Heuvel, M. Preparation of novel diazaspiroalkanes and their use for treatment of chemokine receptor CCR8 mediated diseases. PCT Int. Appl. WO2005040167, 2005, 136.
93. (b) Connolly, S.; Skrinjar, M. Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases. PCT Int. Appl. WO2006107252, 2006, 47.
94. (c) Connolly, S.; Linnanen, T.; Skrinjar, M. Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases. PCT Int. Appl. WO2006107253, 2006, 55.
95. (d) Connolly, S.; Skrinjar, M. Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases. PCT Int. Appl. WO2006107254, 2006, 44.
96. (e) Börjesson, L.; Connolly, S.; Johansson, H.; Kristoffersson, A.; Linnanen, T.; Shamovsky, I.; Skrinjar, M. Preparation of novel diazaspiroalkanes for treatment of CCR8 mediated diseases. PCT Int. Appl. WO2007030061, 2007, 257.
97. + channel structure-activity relationships and mechanisms of drag-induced QT prolongation. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 441-461.
98. Ghosh, S.; Elder, A.; Guo, J.; Mani, U.; Patane, M.; Carson, K.; Ye, Q.; Bennett, R.; Chi, S.; Jenkins, T.; Guan, B.; Kolbeck, R.; Smith, S.; Zhang, C.; LaRosa, G.; Jaffee, B.; Yang, H.; Eddy, P.; Lu, C.; Uttamsingh, V.; Horlick, R.; Harriman, G.; Flynn, D. Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8). J. Med. Chem. 2006, 49, 2669-2672.
99. McCauley, J. A.; Theberge, C. R.; Romano, J. J.; Billings, S. B.; Anderson, K. D.; Claremon, D. A.; Freidinger, R. M.; Bednar, R. A.; Mosser, S. D.; Gaul, S. L.; Connolly, T. M.; Condra, C. L.; Xia, M.; Cunningham, M. E.; Bednar, B.; Stump, G. L.; Lynch, J. J.; Macaulay, A.; Wafford, K. A.; Koblan, K. S.; Liverton, N. J. NR2B-selective N-Methyl-D-aspartate antagonists: Synthesis and evaluation of 5-substituted benzimidazoles. J. Med. Chem. 2004, 47, 2089-2096.
100. Blum, C. A.; Zheng, X.; De Lombaert, S. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: Potent and selective neuropeptide Y Y5-receptor antagonists. J. Med. Chem. 2004, 47, 2318-2325.
101. Kim, D.; Wang, L.; Hale, J. J.; Lynch, C. L.; Budhu, R. J.; MacCoss, M.; Mills, S. G.; Malkowitz, L.; Gould, S. L.; Demartino, J. A.; Springer, M. S.; Hazuda, D.; Miller, M.; Kessler, J.; Hrin, R. C.; Carver, G.; Carella, A.; Henry, K.; Lineberger, J.; Schleif, W. A.; Emini, E. A. Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties. Bioorg. Med. Chem. Lett. 2005, 15, 2129-2134.
102. Dorovska, V. N.; Varfolomeev, S. D.; Kazanskaya, N. F.; Klesov, A. A.; Martinek, K. Influence of the geometric properties of the active center on the specificity of α-chymotrypsin catalysis. FEBS Lett. 1972, 23, 122-124.
103. Fersht, A. R.; Shindler, J. S.; Tsui, W.-C. Probing the limits of protein-amino acid side chain recognition with the aminoacyl-tRNA synthetases. Discrimination against phenylalanine by tyrosyl-tRNA synthetases. Biochemistry 1980, 19, 5520-5524.
104. Choe, H.; Nah, K H.; Lee, S. N.; Lee, H. S.; Lee, H. S.; Jo, S. H.; Leem, C. H.; Jang, Y. J. A novel hypothesis for the binding mode of HERG channel blockers. Biochem. Biophys. Res. Commun. 2006, 344, 72-78.
105. Fernandez, D.; Ghanta, A.; Kauffman, G. W.; Sanguinetti, M. C. Physicochemical features of the hERG channel drug binding site. J. Biol. Chem. 2004, 279, 10120-10127.
106. Needham, M.; Sturgess, N.; Cerillo, G.; Green, I.; Warburton, H.; Wilson, R.; Martin, L.; Barratt, D.; Anderson, M.; Reilly, C.; Hollis, M. Monocyte chemoattractant protein-1: Receptor interactions and calcium signaling mechanisms. J. Leukocyte Biol. 1996, 60, 793-803.
107. Kr potassium channel blocking activity. PCT Int. Appl. WO2005037052, 2005, 22.
108. Murphy, S. M.; Palmer, M.; Poole, M. F.; Padegimas, L.; Hunady, K.; Danzig, J.; Gill, S.; Gill, R.; Ting, A.; Sherf, B.; Branden, K.; Stricker-Krongrad, A. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J. Pharmacol. Toxicol. Methods 2006, 54, 42-55.
109. Donovan, S. F.; Pescatore, M. C. Method for measuring the logarithm of the octanol-water partition coefficient by using short octadecylpoly(vinyl alcohol) high-performance liquid chromatography columns. J. Chromatogr., A 2002, 952, 47-61.
110. a and logD7.4 measurements. PharmaChem 2003, 2, 55-59.